Ipca Laboratories Limited a pharmaceutical company that manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments.
Business Segments
The company operates through five segments: Pharmaceutica…
Analysis
Middle-of-the-road
Ipca Laboratories Limited is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.
The price is expensive. You pay 41.7× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 16% yearly growth; analysts expect 15%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is sturdy. The company scores 17/20 on our value-creation score: strong value creator.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202339
63
2023202420252026
All-time high
90
Jan 2025
All-time low
39
Jan 2023
Average rank
60
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
29
52
65
53
Price/Earnings
37
38
45
68
Price/Book
23
43
55
56
Dividend Yield
37
25
27
24
Value (overall)
24
43
53
55
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.